Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel

Rhea-AI Summary

Scilex Holding Company (Nasdaq: SCLX) announced on Jan 2, 2026 the appointment of Kasowitz LLP and founding partner Marc Kasowitz as its litigation and intellectual property counsel. Kasowitz LLP will advise on complex commercial and patent litigation, IP enforcement and defense, licensing, and strategic IP governance as Scilex advances and protects its pharmaceutical assets and late-stage development pipeline.

A Scilex spokesperson said the appointment strengthens legal capabilities to support commercialization and shareholder value. Company product websites and contact information were provided.

Market Reality Check

$13.09 Last Close

Volume Volume 75,635 is close to the 20-day average of 78,615 (relative volume 0.96). normal

Technical Shares at $12.20 are trading below the 200-day MA of $13.04 and 64.4% below the 52-week high.

Peers on Argus 1 Up

SCLX was down 0.81% pre-news while peers were mixed: IRWD up sharply earlier in momentum scans, AMRN and DERM up modestly, BIOA and CTOR down. Moves appear stock-specific rather than a broad sector swing.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 23	Shareholder perk token	Positive	-8.2%	Confirmation of Dream Bowl 2026 Meme Coin claim process for eligible shareholders.
Nov 26	Strategic investment	Positive	+0.4%	Completion of two-tranche Datavault AI equity financing via pre-funded warrant.
Nov 25	Warrant exercise close	Negative	-8.0%	Closing of reduced-price warrant exercises raising <b>$20.3 million</b> with new warrant issued.
Nov 24	Warrant exercise deal	Negative	-2.3%	Agreement for immediate cash exercise of warrants and issuance of new five-year warrant.
Nov 21	Token distribution update	Positive	+18.8%	Update on planned Dream Bowl 2026 Meme Coin distribution to Scilex record holders.

Pattern Detected

News-driven moves often align with the underlying tone, with one notable selloff on otherwise positive shareholder-perk news.

Recent Company History

Over the last several weeks, Scilex has focused on financing flexibility and strategic digital-asset initiatives. Multiple warrant exercises generated about $20.3 million in gross proceeds and introduced new warrants. The company also expanded a non-recourse loan structure and deepened ties with Datavault AI, securing exposure to shares valued around $583.3 million. Concurrently, Scilex promoted Dream Bowl 2026 Meme Coin distributions as a shareholder perk. Against this backdrop, appointing Kasowitz LLP fits an emphasis on protecting commercial products and intellectual property as these strategies evolve.

Market Pulse Summary

This announcement highlights Scilex’s decision to bolster its litigation and intellectual property capabilities by appointing Kasowitz LLP, a firm with extensive complex commercial and patent litigation experience. In recent months, Scilex has combined equity-linked financings, including about $20.3 million in warrant exercises, with structured non-recourse loans and digital-asset related initiatives. Investors may track how this enhanced legal support interacts with the company’s efforts to commercialize non-opioid pain products, safeguard proprietary assets, and manage financing arrangements.

Key Terms

intellectual property regulatory

"Kasowitz LLP will advise Scilex on complex commercial litigation, patent litigation, intellectual property enforcement"

Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.

patent litigation regulatory

"Kasowitz LLP will advise Scilex on complex commercial litigation, patent litigation, intellectual property enforcement"

A court fight over who has the legal right to make, use or sell a particular invention or product design. For investors it matters because the outcome can block sales, force royalty payments or open the door to wider market access, much like a disputed property line can prevent someone from building or selling on a plot of land and change the expected value of an investment.

cardiometabolic medical

"chronic pain and neurodegenerative and cardiometabolic disease, announced that it has appointed Kasowitz"

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

antitrust regulatory

"high-stakes disputes involving antitrust, securities, banking, and product liability matters"

Antitrust are laws and government actions that stop companies from unfairly dominating markets, fixing prices, or blocking competitors — think of a referee preventing one player from hogging the ball so the game stays fair. Investors care because antitrust investigations, fines, or orders to change business practices can reduce revenue, raise costs, or limit growth, which directly affects a company’s risk profile and valuation.

securities financial

"high-stakes disputes involving antitrust, securities, banking, and product liability matters"

Securities are financial investments that represent a claim on part of a company's assets or earnings, such as stocks or bonds. They are like certificates proving ownership or debt, which can be bought and sold in financial markets. Securities matter to investors because they offer opportunities to grow wealth, earn income, or manage risk through different types of investments.

product liability regulatory

"high-stakes disputes involving antitrust, securities, banking, and product liability matters"

Legal responsibility that a maker, distributor or seller has when a product causes injury or damage because of a design flaw, manufacturing error, inadequate instructions, or missing warnings. It matters to investors because product-liability claims can lead to large legal costs, regulatory fines, costly recalls and lost sales, which reduce profits and can sharply lower a company’s stock price—think of it like a hidden defect that suddenly creates big repair bills and lost trust.

AI-generated analysis. Not financial advice.

PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced that it has appointed Kasowitz LLP and its founding partner Marc Kasowitz as the Company’s litigation and intellectual property counsel.

Kasowitz LLP will advise Scilex on complex commercial litigation, patent litigation, intellectual property enforcement and defense, licensing matters, and strategic intellectual property governance as the Company continues to advance and protect its proprietary pharmaceutical assets and development pipeline. Mr. Kasowitz is a highly experienced U.S. trial lawyer with decades of experience leading high-stakes intellectual property and complex commercial litigation in federal and state courts. His background includes representation in intellectual property disputes involving innovative technologies and life sciences.

Marc E. Kasowitz is a veteran American trial lawyer and the founding managing partner of Kasowitz LLP, a New York-based litigation firm he co-founded in 1993. He is widely recognized for his expertise in complex commercial litigation, having been named among the country’s top trial lawyers by Benchmark Litigation and honored as a Litigation Trailblazer by the National Law Journal. Mr. Kasowitz regularly serves as lead counsel in high-stakes disputes involving antitrust, securities, banking, and product liability matters, representing major corporate clients across a range of industries, and has earned recognition from Chambers USA, The Legal 500, and other legal ranking organizations for his trial experience and advocacy. For more information, click Kasowitz LLP

“Protecting and enforcing our intellectual property portfolio is central to Scilex’s long-term strategy and shareholder value,” said a spokesperson for Scilex. “The appointment of Marc Kasowitz and Kasowitz LLP strengthens our legal capabilities as we continue to commercialize our products and advance our late-stage pipeline.”

For more information on Scilex Holding Company, refer to www.scilexholding.com

For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com

For more information on ZTlido^® including Full Prescribing Information, refer to www.ztlido.com.

For more information on ELYXYB^®, including Full Prescribing Information, refer to www.elyxyb.com.

For more information on Gloperba^®, including Full Prescribing Information, refer to www.gloperba.com.

https://www.facebook.com/scilex.pharm

https://www.linkedin.com/company/scilex-holding-company/

info@scilexholding.com

About Scilex Holding Company

Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido^® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB^®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba^®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA™” or “SP-102”), which is owned by Semnur (a majority owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.

Scilex is headquartered in Palo Alto, California.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, Scilex’s intellectual property goals and processes, future opportunities for Scilex and its subsidiaries, the future business strategies, long-term objectives and commercialization plans of Scilex and its subsidiaries, the current and prospective product candidates, planned clinical trials and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and the related market opportunity of Scilex and its subsidiaries, statements regarding SP-102, if approved by the FDA, Scilex’s potential to attract new capital and avoid the effects of negative debt leverage and other statements that are not historical facts. These statements are based on management’s current expectations of and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Scilex. These statements are subject to a number of risks and uncertainties regarding Scilex’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, general economic, political and business conditions; the ability of Scilex and its subsidiaries to develop and successfully market products; the ability of Scilex and its subsidiaries to grow and manage growth profitably and retain its key employees; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the prior results of the clinical trials may not be replicated; regulatory and intellectual property risks; the risk of failure to realize the anticipated benefits of the transactions contemplated with Datavault and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the SEC. There may be additional risks that Scilex presently does not know or that Scilex currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Scilex’s expectations, plans or forecasts of future events and views as of the date of the communication. Scilex anticipates that subsequent events and developments will cause such assessments to change. However, while Scilex may elect to update these forward-looking statements at some point in the future, Scilex specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Scilex’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements.

Contacts:

Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310

Email: investorrelations@scilexholding.com

Website: www.scilexholding.com

SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.

ZTlido^® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

Gloperba^® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.

ELYXYB^® is a registered trademark owned by Scilex Holding Company.

Scilex Bio™ is a trademark owned by Scilex Holding Company, Inc.

All other trademarks are the property of their respective owners.

© 2026 Scilex Holding Company All Rights Reserved.

FAQ

What did Scilex (SCLX) announce on January 2, 2026 regarding legal counsel?

Scilex appointed Kasowitz LLP and Marc Kasowitz as its litigation and intellectual property counsel.

What legal matters will Kasowitz LLP handle for Scilex (SCLX)?

Kasowitz LLP will advise on commercial and patent litigation, IP enforcement and defense, licensing, and IP governance.

How might the Kasowitz LLP appointment affect Scilex (SCLX) intellectual property strategy?

The firm is expected to strengthen Scilex's IP enforcement and strategic governance as the company advances its pipeline.

When did Scilex (SCLX) publicly announce the Kasowitz LLP appointment?

The appointment was announced on January 2, 2026.

Where can investors find more information about Scilex products mentioned in the announcement?

Investors can visit product sites listed in the release, including ztlido.com, elyxyb.com, and gloperba.com.

Who is Marc Kasowitz and why was he named counsel for Scilex (SCLX)?

Marc Kasowitz is the founding partner of Kasowitz LLP, described as an experienced U.S. trial lawyer with decades of high‑stakes IP and commercial litigation experience.